Clinical Trial Update: The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SCT630 to adalimumab in adults with plaque psoriasis to evaluate efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• SCT630

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Psoriasis | Phase 3 | Status: UNKNOWN